Early in tumor development, circulating tumor cells (CTCs) detach from primary or metastatic lesions and are important ...

Circulating tumor DNA (ctDNA) assays are promising tools for the prediction of cancer treatment response. Here, we build a framework for the design of ctDNA biomarkers of therapy response that ...

Circulating tumor cells were first described in 1869 by Thomas Ashworth, an Australian pathologist who observed them in a peripheral blood sample taken from a patient with metastatic cancer. 1 They ...

Plasma samples, clinical data, and imaging results were collected from 319 patients. A tumor-informed ctDNA assay was used for analysis. Patients were divided into discovery (167 patients) and ...

A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer ...